Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BIRC5 expression is a poor prognostic marker in Ewing sarcoma.

Pooja Hingorani1, Paul Dickman, Pamela Garcia-Filion

  • 1Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ 85016, USA. phingorani@phoenixchildrens.com

Pediatric Blood & Cancer
|September 11, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective intraoperative multi-vessel embolization for placenta accreta spectrum: a doubly robust propensity-weighted analysis of a histologically confirmed cohort.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

Bridging Parallel Disciplines: An Integrated Workshop for Clinical and Imaging Informatics Training.

Journal of imaging informatics in medicine·2026
Same author

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

Use of Tranexamic Acid in Laparoscopic Myomectomy: AAGL Committee Opinion and Practice Guideline Update.

Journal of minimally invasive gynecology·2026
Same author

Impact of improvisational theater training on the resiliency of medical students: a mixed-methods study.

Academic medicine : journal of the Association of American Medical Colleges·2026
Same journal

Comment on: "The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience"-The Evolving Role of the BIT Regimen.

Pediatric blood & cancer·2026
Same journal

Extramedullary Intradural Spinal Tumor in an Infant With Neurocutaneous Melanosis.

Pediatric blood & cancer·2026
Same journal

The Role of Hematopoietic Cell Transplantation in Ataxia-Telangiectasia.

Pediatric blood & cancer·2026
Same journal

Pediatric T-Lymphoblastic Lymphoma With T(9;17) and MIR142HG::NOTCH1 Fusion Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission.

Pediatric blood & cancer·2026
Same journal

Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
Same journal

Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.

Pediatric blood & cancer·2026
See all related articles

Survivin (BIRC5) is overexpressed in Ewing sarcoma (ES) and drives tumor growth. High survivin levels in ES patients indicate a poor prognosis, suggesting it as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The inhibitor of apoptosis protein BIRC5 (Survivin) is overexpressed in various cancers, correlating with poor prognosis.
  • Ewing sarcoma (ES) is the second most common pediatric bone sarcoma, necessitating research into its underlying mechanisms.

Purpose of the Study:

  • To investigate the role and prognostic significance of BIRC5 in Ewing sarcoma.
  • To evaluate BIRC5 as a potential therapeutic target in ES.

Main Methods:

  • Western blot analysis of BIRC5 protein in ES cell lines.
  • Assessment of survivin's functional role using siRNA knockdown and the small molecule inhibitor YM155.
  • Immunohistochemical analysis of BIRC5 in patient tumor samples and correlation with clinical outcomes.

Related Experiment Videos

Main Results:

  • BIRC5 is significantly overexpressed in ES cell lines and patient tumor samples compared to normal tissues.
  • BIRC5 knockdown or inhibition with YM155 reduced ES cell growth and viability.
  • Higher BIRC5 expression in tumors correlated with worse overall survival in ES patients (HR: 6.05, P=0.04).

Conclusions:

  • BIRC5 is overexpressed in Ewing sarcoma and plays a critical role in tumor cell growth and viability.
  • Elevated BIRC5 expression serves as an independent poor prognostic factor in ES patients.